Laurie H. Glimcher, chief executive officer of the Dana-Farber Cancer Institute, announced that she will step down next month, ending an eight-year tenure that capped her surprise split from Dana-Farber’s longtime partner, Brigham and Women’s Hospital, and the decision to build a cancer center with Beth Israel Deaconess Medical Center.

Benjamin L. Ebert, chief of Dana-Farber’s Division of Medical Oncology and an award-winning researcher, will succeed Glimcher on Oct. 1, the Boston-based institute said in a statement Tuesday. In his current role, Ebert is responsible for more than half of Dana-Farber’s 556 faculty members and more than 80 research laboratories.

Glimcher, a highly respected immunologist, will stay at Dana-Farber to continue her work in the laboratory she leads and to supervise the institute’s physicians and scientists.